0

Diabetes Prevention & Education for Prediabetes

AO
KM
Overseen ByKashif Munir, M.D.
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Maryland, Baltimore
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Diabetes Prevention Program (DPP) for prediabetes?

The Diabetes Prevention Program (DPP) is shown to reduce the risk of developing type 2 diabetes by 58% over three years in people with prediabetes. This program focuses on lifestyle changes like diet and exercise, and has been supported by major health organizations.12345

Is the Diabetes Prevention Program (DPP) safe for humans?

The Diabetes Prevention Program (DPP) is a lifestyle change program that has been evaluated in clinical trials and is supported by major health organizations like the American Medical Association and the Centers for Disease Control and Prevention, indicating it is generally safe for humans.12367

How is the Diabetes Prevention Program (DPP) treatment different from other treatments for prediabetes?

The Diabetes Prevention Program (DPP) is unique because it focuses on lifestyle changes, such as diet and exercise, to prevent diabetes, rather than relying on medication or surgery. It has been shown to reduce the risk of developing diabetes by 58% over three years, making it a highly effective non-drug approach for people with prediabetes.13468

What is the purpose of this trial?

Type 2 diabetes mellitus is one of the fastest growing public health problems in developed and developing countries and imposes a large financial burden on health-care systems. Preventing, delaying, and managing diabetes should be a priority for health-care systems. Nationally, 38% of adults have prediabetes, with more than 80% of people with prediabetes being unaware of their condition. In Maryland, an estimated 10.5% of adults report prediabetes, and 33.7% of Baltimore City residents have obesity, an important risk factor for prediabetes.The BMDRP aims to increase the capacity of BMDRP hospitals and community partners to offer DPP and DSMT directly in communities and will also increase the number of referrals into these programs.Successful enrollment and completion of DPP has demonstrated reduced risk of developing type 2 diabetes for individuals with pre-diabetes. However, limited data exist on changes in body composition and liver fat in individuals completing DPP. Individuals with pre-diabetes often have obesity and non-alcoholic fatty liver disease. We will evaluate for changes in body fat and liver fat in individuals completing the DPP program.

Eligibility Criteria

This trial is for adults with prediabetes, obesity, or type 2 diabetes who want to prevent or manage their condition. Participants should have a BMI of at least 25 (or 23 if Asian) indicating overweight status. Those with normal blood sugar levels are not eligible.

Inclusion Criteria

I have type 2 diabetes.
I am pre-diabetic with a BMI of 25 or higher, or 23 if I'm Asian.

Exclusion Criteria

Your blood sugar levels are normal.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Lifestyle Intervention

Participants undergo the Diabetes Prevention Program (DPP) lifestyle intervention, which includes body composition and liver fat analysis

12 months
Regular visits for body composition and liver fat analysis

Follow-up

Participants are monitored for changes in liver elastography, body composition, and diabetes control after completing the DPP

12 months

Treatment Details

Interventions

  • Diabetes Prevention Program (DPP)
  • Diabetes Self-Management Training (DSMT)
Trial Overview The trial tests the Diabetes Prevention Program (DPP) and Diabetes Self-Management Training (DSMT). It aims to see if these programs can reduce the risk of developing type 2 diabetes and improve body composition and liver health in participants.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: InterventionExperimental Treatment1 Intervention
All subjects participating in the diabetes prevention program will be offered body composition analysis and liver fat analysis, before, during, and after the lifestyle intervention

Diabetes Prevention Program (DPP) is already approved in United States for the following indications:

🇺🇸
Approved in United States as Diabetes Prevention Program for:
  • Prediabetes
  • Type 2 diabetes prevention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Maryland, Baltimore

Lead Sponsor

Trials
729
Recruited
540,000+

Findings from Research

The Diabetes Prevention Program (DPP) can reduce the incidence of diabetes by 58% over three years for individuals with prediabetes, yet most patients are unaware of their condition.
With Medicare coverage starting in 2018, the DPP has become more accessible for patients over 65, highlighting the need for healthcare providers to implement screening and referral processes for prediabetes.
Practical Tips for Implementing the Diabetes Prevention Program in Clinical Practice.Jasik, CB., Joy, E., Brunisholz, KD., et al.[2019]
The Veterans Affairs Diabetes Prevention Program (VA-DPP) showed higher fidelity in delivery compared to the usual MOVE! program, indicating it may be more effectively implemented in clinical settings.
Participant satisfaction was generally higher in the VA-DPP, suggesting that this program not only has better implementation but also resonates more positively with participants, which is crucial for long-term success.
Implementation findings from a hybrid III implementation-effectiveness trial of the Diabetes Prevention Program (DPP) in the Veterans Health Administration (VHA).Damschroder, LJ., Reardon, CM., AuYoung, M., et al.[2022]
In a modified Diabetes Prevention Program (DPP) for patients with non-alcoholic fatty liver disease (NAFLD), 79% of participants completed the program, leading to significant weight loss and improvements in liver health indicators over 12 months.
Key improvements included reduced hepatic steatosis and liver enzymes, indicating enhanced liver function, although there was a noted increase in low-density lipoprotein levels.
Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study.Hershman, M., Torbjornsen, K., Pang, D., et al.[2023]

References

Practical Tips for Implementing the Diabetes Prevention Program in Clinical Practice. [2019]
Implementation findings from a hybrid III implementation-effectiveness trial of the Diabetes Prevention Program (DPP) in the Veterans Health Administration (VHA). [2022]
Modification of the diabetes prevention program for the treatment of nonalcoholic fatty liver disease: A pilot study. [2023]
Prevention of Diabetes Through the Lifestyle Intervention: Lessons Learned from the Diabetes Prevention Program and Outcomes Study and its Translation to Practice. [2019]
Weight loss success in metabolic syndrome by telephone interventions: results from the SHINE Study. [2022]
The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. [2022]
Mobile Delivery of the Diabetes Prevention Program in People With Prediabetes: Randomized Controlled Trial. [2022]
Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security